Develops therapies for central nervous system diseases, focusing on treatments for schizophrenia, mood disorders, and insomnia.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing treatments for central nervous system diseases. At the forefront of its development pipeline is roluperidone, the company's lead product candidate aimed at addressing schizophrenia. Additionally, Minerva Neurosciences is pioneering MIN-301, a soluble recombinant form of neuregulin-1b1 protein designed for potential therapeutic use in Parkinson's disease and other neurodegenerative disorders.
In collaboration with Mitsubishi Tanabe Pharma Corporation, Minerva Neurosciences holds a strategic license agreement for the global development, sale, and importation of roluperidone, excluding the Asian market. This partnership underscores the company's commitment to expanding the reach of its innovative therapies worldwide. Originally founded as Cyrenaic Pharmaceuticals, Inc., the company rebranded to Minerva Neurosciences, Inc. in 2013, reflecting its focused mission on neurological treatment advancements.
Established in 2007 and headquartered in Waltham, Massachusetts, Minerva Neurosciences, Inc. operates at the cutting edge of neuropharmacology research. With a robust portfolio of promising drug candidates and strategic partnerships, the company continues to drive innovation in the field, aiming to significantly impact the lives of patients suffering from debilitating CNS disorders globally.